In combination with the results of the present review it becomes even more apparent that there is a strong need for clarification in terms of the PANSS calculation: Although some authors use ...

Background: The PANSS (Positive and Negative Syndrome Scale) is one of the most important rating instruments for patients with schizophrenia. Nevertheless, there is a long and ongoing debate in ...

It appears shareholders were spooked by the size of the reduction in PANSS – a 7.5 improvement on placebo and an 18.2-point fall from baseline – compared to similarly-acting rival therapies in ...

Xanomeline and trospium chloride (KarXT), a novel M1/M4 muscarinic receptor agonist, significantly improves cognitive ...

In the 81-patient phase 1b trial, CVL-231 was able to achieve significant reductions in the Positive and Negative Syndrome Scale (PANSS) of schizophrenia symptoms, compared to both placebo and ...